
Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

Novartis is to present data from four pivotal Phase III trials in two debilitating inflammatory diseases at the American College …

AstraZeneca has launched a new app that helps prostate cancer patients to monitor their PSA levels. It is not the …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

